SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): April 20, 2011
EFT BIOTECH HOLDINGS, INC.
-----------------------------------
(Exact name of Registrant as specified in its charter)
Nevada 000-53730 20-1211204
------------------------------ --------------------- --------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
17800 Castleton Street, Suite 300
City of Industry, CA 91748
-------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (626) 581-3335
--------------
N/A
-----------------------------------------
(Former name or former address if changed since last report)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 21, 2011 Jeffrey Cheung (age 51) was appointed the Company's
Principal Financial and Accounting Officer. Between 2001 and 2010, Mr. Cheung
was the CFO at NetDimensions, a U.K. listed company engaged in software
development with focuses on learning and knowledge management technology. Mr.
Cheung is a fellow member of Certified General Accountants (Canada) and
Association of Chartered Certified Accountants (`ACCA'). He is also a member of
the Hong Kong Institute of Taxation. He began his career as an audit accountant
with Peat Marwick Mitchell & Co. in 1983. Mr. Cheung has served in various roles
with, including financial controller of Oracle (HK) Limited and was a tax
auditor with Revenue Canada. Mr. Cheung holds a BA in accounting and financial
management from the University of Sheffield and an MBA from Sheffield Hallam
University. Mr. Cheung served on the board of the Hong Kong branch of the
Association of Certified General Accountants (CGA-HK) from 2001 - 2007
With the appointment of Mr. Cheung, Jack Jie Qin resigned as the Company's
Principal Financial and Accounting Officer. Mr. Qin remains as the Company's
President, Chief Executive Officer and a Director.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 20, 2011
EFT BIOTECH HOLDINGS, INC.
By: /s/ Jack Jie Qin
----------------------------
Jack Jie Qin, President